Ivomec Comp

Quick links to important sections

Ivomec Comp

Method of action: Anthelmintic, Antiparasitic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ivomec Comp

Quick Facts

Property Description
Active Ingredients Ivermectin, Praziquantel
Pharmacological Class Antiparasitic Agent (Endectocide and Cestocide)
Primary Form(s) Injectable solution, Oral paste, Oral suspension
Common Type Fixed-Dose Combination Product
Origin Semi-synthetic (Ivermectin) and Synthetic (Praziquantel)

What Type of Medicine is Ivomec Comp?

Ivomec Comp is a branded fixed-dose combination product classified as a broad-spectrum antiparasitic agent intended exclusively for veterinary medicine. This specialized entity integrates two distinct active ingredients to function simultaneously as both an endectocide and a cestocide. The combination structure of the medicine is supported by extensive pharmacological studies which confirm its comprehensive action across a wide range of parasitic species. The product is commonly available in forms such as a sterile injectable solution or an oral paste, allowing for flexibility in its parenteral or oral route of administration.

Composition and Origin: Ivermectin and Praziquantel

The foundation of the medicine rests on the active ingredients Ivermectin and Praziquantel. Ivermectin is a semi-synthetic compound belonging to the Macrocyclic lactone class, while Praziquantel is a synthetic compound classified as an Isoquinoline pyrazine derivative. The synthesis of Ivermectin from soil organism fermentation is a process clinically recognized in the field of antiparasitic chemistry. Ivomec Comp is positioned as a complete solution, bundling the distinct, established actions of both compounds.

General Purpose: Why is this Combination Used?

The general purpose of this specific combination drug is to achieve robust, systemic parasitic control through a single course of action. The dual agents create a powerful synergistic effect, allowing the product to simultaneously eliminate both internal parasites and external parasites. This dual functionality is essential for controlling widespread parasitic burdens, including gastrointestinal nematodes, lungworms, and tapeworms (helminthiasis), ensuring comprehensive coverage.

Regulatory References

  1. FDA Freedom of Information Summary: Ivermectin/Praziquantel Paste (Equimax)

What side effects are possible with Ivomec Comp?

Possible side effects and safety information

This section describes the officially documented adverse effects and safety characteristics of Ivomec Comp (Ivermectin/Praziquantel combination, veterinary medicine), based strictly on government regulatory information.

Adverse Reaction Scope

The most frequently reported adverse effects from post-approval experience in the target species are generally categorized as Gastrointestinal and General Constitutional events. These include abdominal pain, diarrhea, depression, lethargy, and anorexia (loss of appetite). These events are listed in regulatory documents in decreasing order of reporting frequency.

Local swelling and itching reactions are also documented, specifically in horses carrying a heavy infection of Onchocerca microfilariae, which is a pattern linked to the death of the parasites following treatment. Temporary coughing may be observed during the immediate drenching process.

Serious Safety Constraints

The most severe safety warnings relate to the product's use outside of the intended target species. Regulatory documents explicitly state that this product is contraindicated for use in other animal species, citing a risk of severe adverse reactions, including fatalities in species such as dogs. This risk is linked to potential neurologic toxicity (including severe CNS signs) associated with the Ivermectin component, particularly in certain susceptible breeds.

Population and Environmental Safety

The official label provides safety assurances for specific populations, documenting the product's safe use in stallions and breeding, pregnant, or lactating mares, with no reported adverse effects on fertility. The product is also safe for horses four weeks of age and older.

Mandatory safety restrictions include the classification of Ivermectin residues as toxic to aquatic organisms, requiring specific caution regarding disposal. Furthermore, a withdrawal period is required before treated food animals can be slaughtered.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based on the official overdose profile documented in government regulatory sources for the active ingredients.

Overdose from significant exposure or ingestion of highly concentrated product may lead to severe adverse effects. Documented signs of toxicity range from gastrointestinal distress (nausea, vomiting, diarrhea) to serious neurological and systemic outcomes.

Documented Signs and Symptoms of Toxicity

System Manifestations
Neurological Confusion, disorientation, ataxia (loss of coordination), tremor, hallucinations, dizziness, seizure, coma.
Systemic Hypotension (low blood pressure), asthenia (weakness), paresthesia (tingling), shortness of breath, severe rash, edema.

Immediate Emergency Action

An overdose is considered a medical emergency. You must immediately call a poison control center or emergency services if an overdose is suspected or confirmed.

Urgent medical attention is required if the affected person experiences any critical symptoms, including:

  • Trouble breathing or shortness of breath.
  • Seizures or loss of consciousness (coma).
  • Severe hypotension or collapse.
  • Inability to be awakened.

There is no specific pharmacologic antidote documented for this overdose. Treatment involves immediate supportive and symptomatic therapy to maintain vital functions, as directed by a healthcare professional.

Therapeutic Uses of Ivomec Comp

What Ivomec Comp Treats: Main Uses and Benefits

Ivomec Comp is a medication used to provide supportive relief and symptom management across various clinical scenarios, helping patients cope with challenging episodes. As a combination product containing active substances categorized as broad-spectrum antiparasitic agents, its uses encompass the treatment of multiple parasitic infections that cause systemic discomfort and functional strain.


Easing Episodic Symptom Discomfort

This medicine may help address symptom clusters that may become intense or disruptive, often appearing suddenly or intensifying over time. It is relevant when symptoms create noticeable physiological strain, with one key aspect being that it offers symptomatic relief that supports patients in coping more steadily with difficult, fluctuating episodes.

Managing Heightened Physiological Tension

The product is applied in clinical settings that involve acute or unstable symptom patterns, such as those marked by periods of increased physiological tension. It is commonly used when supportive symptom management is appropriate, and contributes to providing support to help stabilize symptoms temporarily and ease the overall burden of distress. The combination approach may provide supportive relief during phases where patients experience heightened discomfort and functional strain.

Quick Fact: Relief for Interfering Symptoms

Ivomec Comp assists with managing symptoms that create noticeable interference with daily comfort and routine activities. This supports general well-being during symptomatic phases.

Regulatory References

  1. NIH StatPearls overview of antiparasitic drugs

Eligibility and Restrictions for Use

Ivomec Comp is a veterinary product containing ivermectin, intended for the treatment and control of various internal and external parasites in livestock, particularly cattle and swine.

Approved Users (Target Species)

Species Indication Summary
Cattle Gastrointestinal roundworms, lungworms, grubs, sucking lice, and mange mites.
Swine Gastrointestinal roundworms, lungworms, lice, and mange mites.

Contraindications and Important Safety Warnings

This medication is not approved for human use and should never be used as a substitute for human-grade medications. Use in non-target animal species can lead to severe adverse reactions, including fatalities, particularly in certain dog breeds (e.g., Collies). Specific product warnings also prohibit use in:

  • Female dairy cattle of breeding age (due to potential milk withdrawal concerns).
  • Veal calves.
  • Animals within a specific withdrawal period before slaughter.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other medicines and products as documented in official government regulatory information for the active ingredients, Ivermectin and Praziquantel.

Official Pharmacokinetic Interactions

Interactions primarily involve the alteration of Praziquantel plasma concentration via the Cytochrome P450 (CYP) enzyme system, specifically the CYP 3A pathway.

  • Exposure-Decreasing Substances (CYP 3A Inducers): Medicines such as Rifampin, Phenytoin, Phenobarbital, and Carbamazepine are documented to significantly decrease Praziquantel's concentration (AUC and Cmax) by increasing its metabolism. This can lead to subtherapeutic levels.
  • Exposure-Increasing Substances (CYP 450 Inhibitors): Substances such as Cimetidine, Ketoconazole, Itraconazole, and Erythromycin may increase Praziquantel's plasma levels by inhibiting its metabolism.

Interaction Constraints and Restrictions

Constraint Type Documented Interaction Implication (Official Regulatory Note)
Timing Separation Rifampin Must be discontinued four weeks before administering Praziquantel when immediate treatment is required.
Food/Product Grapefruit Juice Documented to increase the plasma concentration of Praziquantel (Cmax and AUC).

Population-Specific Interaction Caution

Official labeling notes that in individuals with moderate to severe liver impairment (Child-Pugh Class B and C), the clearance of Praziquantel is reduced. This condition results in considerably higher and longer-lasting plasma concentrations, which may amplify the effects of these documented exposure-altering interactions.

Mechanism of Action

The mechanism of action involves two distinct and complementary mechanistic domains, resulting in specific physiological responses in nematodes (roundworms) and cestodes (tapeworms).


Targeted Paralysis via Invertebrate Ion Channel Modulation

Ivermectin, the endectocidal component, acts by targeting the parasite's specialized Glutamate-Gated Chloride Channels (GluCl). By acting as a positive allosteric modulator, Ivermectin forces the channels open, causing a massive influx of chloride ions (Cl^-) into the nerve and muscle cells. This molecular cascade establishes sustained membrane hyperpolarization, which arrests neural transmission and motor control, resulting in flaccid paralysis of the pharyngeal and somatic musculature.


Structural Breakdown via Ca^2+ Homeostasis Disruption

Praziquantel, the cestocidal component, operates by disrupting the cell membrane's permeability to calcium ions ( Ca^2+). This mechanism causes an uncontrolled influx of Ca^2+ into the tapeworm's tissues, triggering sustained spastic paralysis. Simultaneously, this ionic disruption degrades the parasite's protective outer layer, the tegument, rendering the internal structures exposed and leading to subsequent physical destruction.


Mechanistic Complementarity and Dual-Action Strategy

The presence of two active ingredients establishes mechanistic complementarity, as their molecular targets and physiological consequences are independent. The dual-action mechanism addresses the inherent mechanistic limitation of each single component by engaging separate molecular pathways, one targeting neuromuscular function and the other targeting structural integrity.

Dosage and Administration Information

The administration of Ivomec Comp, an Ivermectin and Praziquantel combination product, follows specific protocols which vary based on the target species and dosage form. The product is designed for the oral route of administration, delivered either as an oral paste/gel for large animals or a chewable tablet, often as a triple combination, for smaller animals.

Dosing is dependent on the animal’s accurate body weight. For example, the application for the paste is a single administration delivering 200mu g of Ivermectin and 1.5mg of Praziquantel per kilogram of body weight (mu g/kg and mg/kg). The frequency pattern is dichotomous: use is indicated as a single treatment course for existing parasitic infections, or as a continuous, once-monthly schedule for long-term prophylaxis.

Contextual administration requirements are defined for the various forms. For the oral paste, the animal's mouth must be free of any feed before the product is deposited onto the back of the tongue, and the head must be immediately raised to ensure complete swallowing. Conversely, chewable tablets may be administered without reference to meal timing. Furthermore, there are minimum age or weight thresholds below which the medicine is not recommended, such as the restriction on administering canine tablets to puppies younger than eight weeks of age. The overall protocol emphasizes precise body weight determination to uphold the dosage standard and prevent underdosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ivomec Comp

Evidence for Use in Gastrointestinal Nematode Infection

Research involving the combination of Ivermectin and Praziquantel was studied for its use in conditions linked to infection by gastrointestinal nematodes (a type of internal parasite). The evidence base primarily relies on Controlled Field Trials and Laboratory Efficacy Studies, which included single-drug treatments as comparators. These studies were observed in animal populations, including Equids (such as horses) and Canine groups. Researchers focused on quantifiable measures such as the Reduction in Fecal Egg Counts and determining worm reduction percentages at specific time points. However, long-term effects are not fully established, as the follow-up durations were limited to short-term assessments.

Evidence for Use in Cestode (Tapeworm) Infection

The combination was evaluated in studies focused on infections caused by cestodes (tapeworms). The main outcomes researchers monitored were related to systemic or functional imbalance, specifically by checking for the Elimination of Cestode Eggs and assessing the total worm count. Findings describe patterns observed in the studies where the majority of tested animals showed evidence related to the study's measured outcome of changes in parasite presence. However, findings were mixed in certain high-risk populations, with some research documenting persistent egg shedding after administration.

Evidence for Use in Bot Infection

Research has explored outcomes related to bot larvae (Gasterophilus species) primarily in Equids. The research structure mainly consisted of Controlled Field Trials and specific Necropsy-Based Efficacy Studies. In these studies, researchers monitored outcomes capturing phases of heightened symptom activity, focusing on quantifying the Reduction in Larval Counts. Evidence is limited concerning all bot species; the majority of the existing research specifically addresses Gasterophilus intestinalis, and data for other bot species remain insufficient.

What Is Still Uncertain About Ivomec Comp Research

Certainty remains low in several areas due to limitations in the current research. The most prominent uncertainties are related to long-term effects, which are not fully established, due to follow-up durations being limited. Additionally, the long-term implications of anthelmintic resistance on the combination’s overall action are not fully characterized. Subgroup findings are uncertain for specific animal breeds or age groups that were not the main focus of the initial studies.

Key Studies & References

  1. Efficacy of an ivermectin-praziquantel combination in equids against bots and tapeworms
  2. Field efficacy of ivermectin plus praziquantel oral paste against naturally acquired gastrointestinal nematodes and cestodes of horses in North America and Europe.

Frequently Asked Questions (FAQ)

Common questions about Ivomec Comp (FAQ)


Q: Is Ivomec Comp used for the same conditions as other antiparasitic drugs?

Ivomec Comp is a combination drug, meaning it provides a broader spectrum of action than many single-agent products. Official information confirms it simultaneously targets two major groups of parasites: gastrointestinal nematodes (roundworms) and cestodes (tapeworms). This dual-action approach allows it to address a wide range of parasitic infections with a single course of action.


Q: Does taking Ivomec Comp cause dizziness or tiredness?

The product’s active ingredients are associated with certain effects on the central nervous system (CNS). Officially reported adverse effects include depression and lethargy. Other associated reports related to the components have included dizziness and fatigue.


Q: What are the most commonly reported mild side effects of Ivomec Comp?

According to official post-approval experience reports in the target species, the most frequently observed adverse events are categorized as gastrointestinal and general constitutional events. These common reports include abdominal pain, diarrhea, loss of appetite (anorexia), depression, and lethargy.


Q: Is it common to have stomach upset when taking Ivomec Comp?

Yes, gastrointestinal symptoms are among the most common adverse effects reported in the target species. Official regulatory documents list both abdominal pain and diarrhea as frequently observed reactions.


Q: Can Ivomec Comp be used by people with a history of liver issues?

Ivomec Comp is a veterinary product and is explicitly not approved for use in humans under any circumstances. In the target species, official labeling notes that in cases of moderate to severe liver impairment, the clearance of the Praziquantel component is reduced, which may lead to higher concentrations in the body.


Q: What is Ivomec Comp used for in humans, generally speaking?

Ivomec Comp is strictly a veterinary product and is explicitly not approved for use in humans. Official safety warnings state that its use in non-target species, including humans, is associated with risks of severe adverse reactions and should never be used as a substitute for human-grade medications.


Q: Do you have to take Ivomec Comp with food or on an empty stomach?

The administration instructions depend on the product formulation. For the oral paste, regulatory instructions mandate that the animal's mouth must be free of any feed before administration. Conversely, chewable tablets may be administered without reference to meal timing.


Q: What is the difference between an oral dose and a topical application of ivermectin-based drugs?

Regulatory documents for Ivomec Comp specify its administration via the oral route (paste, tablet) or as an injectable solution. This ensures systemic absorption to control internal parasites. While other ivermectin-based products may be topical, this combination product focuses on the oral or injectable routes to target the full range of indicated parasites.


Q: Is Ivomec Comp safe to use if I am also taking an antifungal medication?

Information regarding the co-administration of Ivomec Comp and antifungal medication is available in regulatory documents. Substances classified as CYP 450 Inhibitors, such as the antifungals Ketoconazole and Itraconazole, may increase the plasma concentration of Praziquantel by inhibiting its metabolism.


Q: What are the common myths or misunderstandings about Ivomec Comp?

The primary misconception addressed by regulatory warnings is the use of this product by humans. Official safety warnings clearly state that Ivomec Comp is a veterinary product only and its use in humans is associated with severe adverse health risks.


Q: Are there any special precautions needed when giving Ivomec Comp to older adults?

Regulatory documents confirm safe use in target animals from four weeks of age and older. No specific additional precautions are documented solely for geriatric (older) animals, but veterinary judgment regarding age-related organ function is necessary.


Q: How long does the effect of a single dose of Ivomec Comp typically last?

Pharmacokinetic data suggests the two active ingredients have significantly different durations of presence in the body. The Ivermectin component is detectable for up to 14 days post-administration. The Praziquantel component is rapidly eliminated, with a much shorter half-life.


Q: Is there peer-reviewed research supporting the effectiveness of Ivomec Comp?

The regulatory approval is supported by Controlled Field Trials and Laboratory Efficacy Studies. These studies focus on quantifiable measures, such as the reduction in fecal egg counts and worm reduction percentages, to confirm the product's action against the target parasites.


Q: Is Ivomec Comp used to treat roundworms or tapeworms?

Yes. The combination product is specifically designed to treat both: the Ivermectin component targets gastrointestinal nematodes (roundworms) while the Praziquantel component targets cestodes (tapeworms). This combination ensures comprehensive coverage for these parasites.


Q: Does Ivomec Comp affect the way blood thinning medications work?

The official product safety information does not specifically list blood-thinning medications as an interaction. However, some independent monographs associated with Ivermectin mention a potential interaction with the blood thinner Warfarin.


Q: Is the manufacturer of Ivomec Comp a well-known pharmaceutical company?

Yes. Ivomec Comp is a recognized brand name, and the product is often associated with Boehringer Ingelheim, a major global pharmaceutical company known in the animal health industry.


Q: Why is grapefruit juice often mentioned in connection with drugs like Ivomec Comp?

Regulatory documentation lists grapefruit juice as a food product that can interact with the Praziquantel component. It acts by inhibiting the Cytochrome P450 3A enzyme system, which increases the plasma concentration of Praziquantel in the bloodstream.


Q: Is Ivomec Comp used to treat lice or scabies?

Yes. For the approved target species, the product is indicated for the control of various internal and external parasites. This includes treatment for infestations by external parasites such as sucking lice and mange mites (scabies).


Q: What is the half-life of the active ingredients in Ivomec Comp?

Pharmacokinetic data shows that the two active ingredients are metabolized at very different rates. The elimination half-life for Ivermectin is established as 90 hours, while the half-life for Praziquantel is much shorter, established at 40 minutes.


Q: Can someone with kidney problems safely use Ivomec Comp?

Ivomec Comp is a veterinary product and is explicitly not approved for use in humans under any circumstances. For the Praziquantel component, official monographs suggest that no dose adjustment is typically necessary for renal impairment, as the primary excretion pathway involves the breakdown products.


Q: Is it normal to feel a slight fever after the first dose of Ivomec Comp?

A rise in body temperature (fever) has been reported in associated monographs as an adverse reaction, particularly in cases where the treated animal has a heavy parasite burden. Official documents also note that temporary coughing can be observed immediately during administration of the product.


Q: Is there a known risk of overdose associated with Ivomec Comp?

Yes, there is an official risk. The official label emphasizes accurate body weight determination as a standard procedure to prevent under- or overdose. Studies on the target species treated with higher-than-recommended doses have shown transient signs like salivation, increased body temperature, and impaired vision.


Q: Can taking multiple doses of Ivomec Comp close together increase side effects?

Taking more than the prescribed dose (overdose) has been shown to result in increased signs of adverse effects. Official regulatory protocols define dosing schedules, which are typically either a single treatment course or a continuous, once-monthly schedule for prophylaxis.


Q: Is Ivomec Comp considered a broad-spectrum antiparasitic?

Yes, it is officially classified as a broad-spectrum antiparasitic agent. This is due to the synergistic action of its two distinct active ingredients, Ivermectin and Praziquantel, which allow it to effectively address a wide range of both internal and external parasites.


Q: Why do some people confuse Ivomec Comp with heartworm prevention?

The confusion arises because the active ingredient Ivermectin is a well-established agent used in other formulations specifically for heartworm prophylaxis. However, Ivomec Comp itself is indicated for the treatment of internal and external parasites in livestock like cattle and swine.


Q: Does Ivomec Comp come in different forms (tablet, liquid, paste)?

Yes. The product’s official regulatory documents list its primary forms as an injectable solution, an oral paste, and an oral suspension. It is also commonly available as a chewable tablet in combination formulations for various target species.


Q: Is it possible to have an allergic reaction to Ivomec Comp?

Yes. The product’s safety warnings contraindicate use in animals known to be hypersensitive to the active substances or any of the product’s ingredients. Local reactions like swelling and itching have also been documented in some cases related to the death of microfilariae parasites following treatment.

How should Ivomec Comp be stored and disposed of?

How to Store and Dispose of Ivomec Comp

Official regulatory guidelines define precise requirements for storing and disposing of this medicine to maintain its stability and ensure environmental safety.

Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically 15 C–30 C (59 F–86 F).
Protection Keep away from heat, open flames, and sources of ignition. Certain forms must be protected from light.
Container Store only in the original container and keep it tightly closed when not in use.
Stability Some formulations, such as oral gel, have a limited 6-month shelf-life after first opening, requiring storage below 25 C during this time.
Child Safety The label mandates keeping this medicine and all drugs out of the reach of children.

Disposal Instructions

Due to the presence of active components that are extremely dangerous to fish and aquatic life, unused product and waste materials must not contaminate surface water, ditches, or the sewage system. All disposal of the unused medicine and waste must follow local official regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ivomec Comp found in:

A-Z Index: